首页> 美国卫生研究院文献>Polymers >Nanoparticle-Hydrogel Composite Drug Delivery System for Potential Ocular Applications
【2h】

Nanoparticle-Hydrogel Composite Drug Delivery System for Potential Ocular Applications

机译:纳米粒子水凝胶复合药物输送系统用于潜在的眼镜应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Intravitreal injections are clinically established procedures in the treatment of posterior eye diseases, such as wet age-related macular degeneration (wet AMD) which requires monthly intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) protein drugs that can lead to complications due to frequent dosing. In this study, we designed a composite drug delivery system (DDS) consisting of drug-loaded poly (lactide–co–glycolide) (PLGA) nanoparticles and a chemically crosslinked hyaluronan hydrogel to reduce the dosing frequency. The morphology, size, composition, and drug loading efficiency of the prepared nanoparticles were characterized. The properties of the modified hyaluronan polymers used were also examined. The degree of swelling/degradation and controlled release ability of the hyaluronan hydrogel and the composite DDS were identified using bovine serum albumin (BSA) as a model drug. The results show that this system can retain 75% of its wet weight without losing its integrity and release the model drug at the rate of 0.4 μg/day for more than two months under physiological conditions. In addition, the nanoparticulate formulation of the system can further improve bioavailability of the drugs by penetrating deep into the retinal layers. In conclusion, the proposed composite DDS is easily prepared with biocompatible materials and is promising for providing the sustained release of the protein drugs as a better treatment for ocular neovascular diseases like wet AMD.
机译:玻璃体内注射是在临床上确定后眼部疾病的程序,例如潮湿年龄相关的黄斑变性(湿AMD),其需要每月含有可能导致并发症的抗血管内皮生长因子(抗VEGF)蛋白质药物由于频繁给药。在该研究中,我们设计了一种由载药的聚(丙交酯 - 共乙酰化)(PLGA)纳米颗粒和化学交联的透明质酸水凝胶组成的复合药物递送系统(DDS),以减少给药频率。表征制备纳米颗粒的形态,尺寸,组成和药物负载效率。还检查了所用修饰的透明质酸聚合物的性质。使用牛血清白蛋白(BSA)作为模型药物鉴定透明质酸水凝胶和复合DDS的溶胀/降解和控制释放能力。结果表明,该系统可以保留其湿重量的75%,而不会在生理条件下以0.4μg/天的速度损失其完整性并将模型药物释放超过两个月。此外,该系统的纳米颗粒制剂可以通过深入到视网膜层中进一步提高药物的生物利用度。总之,所提出的复合物DDS易于用生物相容性材料制备,并且有希望为蛋白质药物的持续释放为湿AMD等眼部血管疾病的更好处理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号